StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Sarepta Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $111.01M. For fiscal 2025 it was -$205.48M. The highest annual figure on record is $107.47M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$205.48M–
FY2024Dec 31, 2024-$205.79M–
FY2023Dec 31, 2023-$500.99M–
FY2022Dec 31, 2022-$325.35M–
FY2021Dec 31, 2021-$443.17M-512.4%
FY2020Dec 31, 2020$107.47M–
FY2019Dec 31, 2019-$456.46M–
FY2018Dec 31, 2018-$388.66M–
FY2017Dec 31, 2017-$232.00M–
FY2016Dec 31, 2016-$245.82M–
FY2015Dec 31, 2015-$149.47M–
FY2014Dec 31, 2014-$128.54M–
FY2013Dec 31, 2013-$64.70M–
FY2012Dec 31, 2012-$29.69M–
FY2011Dec 31, 2011-$23.68M–
FY2010Dec 31, 2010-$15.21M–
FY2009Dec 31, 2009-$8.80M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$197.07M-24.6%
Q1 FY2026Mar 31, 2026-$202.68M–
Q4 FY2025Dec 31, 2025$131.21M+42.5%
Q3 FY2025Sep 30, 2025-$14.59M–
Q2 FY2025Jun 30, 2025$261.34M+1649.0%
Q1 FY2025Mar 31, 2025-$583.44M–
Q4 FY2024Dec 31, 2024$92.05M–
Q3 FY2024Sep 30, 2024-$70.70M–
Q2 FY2024Jun 30, 2024$14.94M–
Q1 FY2024Mar 31, 2024-$242.08M–
Q4 FY2023Dec 31, 2023-$54.66M–
Q3 FY2023Sep 30, 2023-$114.71M–
Q2 FY2023Jun 30, 2023-$122.23M–
Q1 FY2023Mar 31, 2023-$209.40M–
Q4 FY2022Dec 31, 2022-$92.39M–
Q3 FY2022Sep 30, 2022-$64.96M–
Q2 FY2022Jun 30, 2022-$66.82M–
Q1 FY2022Mar 31, 2022-$101.18M–
Q4 FY2021Dec 31, 2021-$29.33M–
Q3 FY2021Sep 30, 2021-$124.33M–
Q2 FY2021Jun 30, 2021-$109.15M–
Q1 FY2021Mar 31, 2021-$180.37M-128.7%
Q4 FY2020Dec 31, 2020-$174.54M–
Q3 FY2020Sep 30, 2020-$238.19M–
Q2 FY2020Jun 30, 2020-$107.60M–
Q1 FY2020Mar 31, 2020$627.79M–
Q4 FY2019Dec 31, 2019-$163.80M–
Q3 FY2019Sep 30, 2019-$67.43M–
Q2 FY2019Jun 30, 2019-$79.00M–
Q1 FY2019Mar 31, 2019-$146.23M–
Q4 FY2018Dec 31, 2018-$122.42M–
Q3 FY2018Sep 30, 2018-$113.32M–
Q2 FY2018Jun 30, 2018-$117.25M–
Q1 FY2018Mar 31, 2018-$35.67M–
Q4 FY2017Dec 31, 2017-$31.06M–
Q3 FY2017Sep 30, 2017-$57.90M–
Q2 FY2017Jun 30, 2017-$85.15M–
Q1 FY2017Mar 31, 2017-$57.89M–
Q4 FY2016Dec 31, 2016-$81.23M–
Q3 FY2016Sep 30, 2016-$60.62M–

More Sarepta Therapeutics figures

See a number that looks wrong?